Skip to content Skip to footer
Subscribe Now

NEWS

Bayer
Bayer Reports P-III (OCEANIC-STROKE) Trial Data on Asundexian for Secondary Stroke Prevention
Shots: The P-III (OCEANIC-STROKE) trial assessed asundexian (50mg, QD, PO) vs PBO, both in combination with antiplatelet therapy, in pts (n=12,327) for prevention of ischemic stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack Trial showed a 26% reduction in recurrent ischemic stroke without increased ISTH major bleeding across all subgroups, met key…
February 6, 2026
Eisai and Henlius Partner to Commercialize Serplulimab in Japan
Shots: Eisai & Henlius have entered into an exclusive commercialization & co-exclusive development & manufacturing license agreement for serplulimab (Hetronifly in the EU) in Japan As per the deal, Eisai will obtain exclusive rights to commercialize serplulimab in Japan in exchange for $75M upfront, ~$80.01M in regulatory milestones, ~$233.3M in sales milestones, with double-digit royalties…
February 6, 2026
Hims & Hers Launches Multi-Cancer Blood Test by Galleri
Shots: Hims & Hers Health has launched access to the Multi-Cancer Test by Galleri, offering a simple blood test for early cancer screening The Hims & Hers Multi-Cancer Test by Galleri detects a shared signal from 50+ cancers, incl. those without recommended screenings, & can be taken annually to help identify cancers early, often before…
February 5, 2026
Evogene and Shanghai Lishan Biopharmaceuticals Partner for BMC128
Shots: Biomica (Evogene’s subsidiary) & Shanghai Lishan Biopharmaceuticals have entered into an exclusive worldwide licensing agreement for BMC128, currently in P-I trial As per the deal, Lishan Biotech will receive exclusive rights to develop, manufacture, & commercialize BMC128, with Biomica receiving development milestone payments & royalties on future commercial sales Lishan Biotech is planning to…
February 5, 2026
Alvotech Reveals PK Data on AVT80 (Biosimilar, Entyvio)
Shots: Alvotech reported positive top-line data from the AVT80-GL-P01 PK study comparing AVT80 with Entyvio in healthy adults The study met all 1EP, demonstrating PK similarity between AVT80 & Entyvio following a single 108mg/0.68mL SC dose, supporting AVT80’s biosimilar profile Alvotech is developing AVT16 (IV) & AVT80 (SC) as Entyvio’s biosimilars, with the AVT80-GL-P01 study…
February 5, 2026
Load more